Delivery Order SPE2DB24D2205-SPE2DB26FDSNL
- Not listed
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $96,699.54 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on September 5, 2025, with completion scheduled for September 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and...
- The Defense Logistics Agency (DLA) awarded a $11,458.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on June 13, 2025, with an ultimate completion date of June 16, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,721.25 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on September 5, 2025, with a completion date of September 8, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under a larger indefinite delivery contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,036.96 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on June 2, 2025, with completion scheduled for June 3, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of pharmaceutical procurement through the DLA's medical supply chain. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a $53,153.38 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors on July 14, 2025, with completion targeted for July 15, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was competitively procured...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,906.97 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside, competitively awarded contract uses firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through...
- The Defense Logistics Agency awarded a delivery order valued at $4,630.35 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed price delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB26FDSNLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,278.76 to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999 and extending through December 2026. The delivery is scheduled for completion by October 21, 2025, with performance to take place at the company's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp serves as a primary pharmaceutical distributor for federal military and veteran healthcare systems, leveraging its comprehensive IDC to supply an extensive range of medications and medical supplies across multiple therapeutic areas. As a major pharmaceutical distributor and healthcare solutions provider, the company fulfills critical medical procurement needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. This delivery order exemplifies the company's ongoing role in supplying specialty medications to support military healthcare programs, with Dupixent being a brand-name biologic treatment for conditions including atopic dermatitis and eosinophilic asthma commonly used within military medical facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.3k | 10/20/25 |